The Patent Trial and Appeal Board (PTAB) has once again confirmed that the Broad Institute, alongside the Massachusetts Institute of Technology and Harvard University, holds priority in the patent for CRISPR-Cas9 gene editing technology in eukaryotic cells. This ruling comes as a remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) and reiterates the Board’s earlier conclusions regarding the inventive contributions of these institutions.
Background of the CRISPR Patent Debate
The CRISPR technology has sparked significant interest and controversy within the scientific and legal communities. Jennifer Doudna and Emmanuelle Charpentier, who were awarded the Nobel Prize in Chemistry in 2020 for their contributions to CRISPR, have been engaged in a prolonged patent dispute with the Broad Institute. The crux of the matter centers around claims of simultaneous invention, which has complicated the patent landscape for this groundbreaking gene-editing tool.
Court’s Prior Rulings and Their Implications
In May 2025, the CAFC issued a pivotal decision that overturned the PTAB’s previous findings, asserting that the Board had misapplied the standard for evaluating the Regents of the University of California and their collaborators (CVC). The court clarified that the burden of proof should not require demonstrable success in experiments to establish conception of an invention. This ruling pushed the PTAB to reassess its earlier conclusions under a modified framework.
Despite this reversal concerning conception, the CAFC upheld the PTAB’s finding that the CVC’s provisional applications from 2012 did not adequately describe a functioning CRISPR-Cas9 system in eukaryotic cells. The court noted that although these applications outlined the essential components, they fell short of demonstrating possession of a working system, thus hindering CVC’s ability to claim constructive reduction to practice.
Revisiting the Evidence: PTAB’s Second Review
During the second review, the PTAB maintained its stance, stating that CVC failed to prove that its inventors had conceived of an embodiment of the invention before the Broad inventors successfully reduced it to practice. The Board emphasized the need to evaluate the totality of evidence and the skill level of an ordinarily skilled artisan at that time.
The PTAB addressed the CAFC’s concerns regarding its earlier conflation of conception and reduction to practice, clarifying that it would consider all evidence without being constrained to specific types of testimony. The Board reiterated that the uncertainty expressed by CVC’s scientists about their experimental outcomes did not negate the evidence from Broad’s inventors, who had achieved practical results first.
The Standard of Evidence and Its Impact
The Board found that the evidence presented—pertaining to the skills of those in the field, testimony from CVC’s witnesses, and the CAFC’s earlier ruling on written description—demonstrated that an ordinary artisan could not have successfully implemented a functioning eukaryotic CRISPR-Cas9 system based solely on CVC’s alleged conception. This highlights the importance of having not just theoretical knowledge but also practical application in patent claims.
Furthermore, the PTAB rejected CVC’s assertion that Broad’s inventors derived their work from CVC. The Board indicated that to substantiate a claim of derivation, it was essential for CVC to prove that it conceived the claimed subject matter prior to Broad, which it failed to do.
The Future of CRISPR Patenting
The implications of this ruling extend beyond the immediate parties involved. The decision reinforces the importance of clear documentation and demonstration of both conception and reduction to practice in patent applications, especially in fast-evolving fields like gene editing.
As CRISPR technology continues to develop and find applications across various industries, the outcomes of these patent disputes will likely influence future research and investment in genetic engineering.
Key Takeaways
- The PTAB has reaffirmed Broad Institute’s patent priority for CRISPR-Cas9 in eukaryotic cells.
- The CAFC’s prior ruling clarified the standards for proving conception in patent law.
-
The PTAB emphasized the importance of both theoretical and practical aspects in patent claims.
-
CVC’s earlier provisional applications were deemed insufficient for establishing a working CRISPR-Cas9 system.
-
The outcome of this case could shape the landscape of gene editing patents and innovation.
In conclusion, the ongoing legal battles surrounding CRISPR technology exemplify the complexities of patent law in rapidly advancing scientific fields. Clarity in the conception and reduction to practice will remain critical as stakeholders navigate these waters. As innovations emerge, the implications of these rulings will undoubtedly continue to influence the development and commercialization of gene-editing technologies.
Read more → ipwatchdog.com